Abbott Laboratories Hits New 52-Week Low at USD 102.44

Abbott Laboratories has reached a new 52-week low, trading at USD 102.44 as of March 24, 2026. This significant drop highlights the stock's recent performance, which has seen a decline of 3.19% over the past year, contrasting sharply with the S&P 500's gain of 13.68% during the same period. The company, a prominent player in the Pharmaceuticals & Biotechnology industry with a market capitalization of USD 214,677 million, maintains a price-to-earnings (P/E) ratio of 32.00. Despite the current low price point, Abbott Laboratories has demonstrated a strong ability to manage its debt, evidenced by a low debt-to-equity ratio of 0.10 and a debt-to-EBITDA ratio of 0.62 times. In terms of operational performance, Abbott has reported positive results for the last three consecutive quarters, with an operating cash flow peaking at USD 9,037 million. The company has also shown healthy long-term growth, with an annual operating profit increase of 13.45%. As it navigates the current market landscape, Abbott Laboratories continues to reflect an attractive valuation compared to its peers.